Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Zynerba Pharmaceuticals (Nasdaq: ZYNE) has announced that CEO Armando Anido will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 1:30 p.m. ET. The presentation will focus on Zynerba's innovative transdermal cannabinoid therapies for rare neuropsychiatric disorders.
Investors can arrange virtual meetings with the management team via Needham's conference coordinator. A webcast will be available on Zynerba's website, with an archived replay accessible for 60 days post-event.
- None.
- None.
DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m. ET.
Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the Needham conference coordinator. A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com. An archived replay will be available on the Company’s website following the event for 60 days.
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. These and other risks are described in the Company’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Contact
Peter Vozzo
Westwicke/ICR
Office: 443-213-0505
Cell: 443-377-4767
peter.vozzo@westwicke.com
FAQ
When will Zynerba Pharmaceuticals present at the Needham Virtual Healthcare Conference?
Who is presenting for Zynerba Pharmaceuticals at the Needham Conference?
Where can I watch the Zynerba Pharmaceuticals presentation?
Is there an opportunity to meet Zynerba Pharmaceuticals management during the conference?
How long will the archive of the Zynerba Pharmaceuticals presentation be available?
